Business Context and Reporting Period
Cocrystal Pharma, Inc. filed this Form 8-K on February 8, 2018, reporting the resolution of litigation and disputes involving Daniel Fisher, his spouse Sharon Fisher, and 580 Garcia Properties LLC. The filing details a series of transactions concluded on or about February 8, 2018, which settled all outstanding claims between the parties.
Key Financial Metrics
- Transaction Proceeds: The Company received $1,400,000 on February 9, 2018, from a third party.
- Asset Carrying Value: The Mortgage Note transferred in the transaction was carried on the balance sheet as a $1.294 million asset.
- Recognized Gain: Approximately $106,000 will be reported as a gain for the current quarter following appropriate write-downs.
- Liquidity and Debt: The filing does not provide updated total cash, debt, or liquidity metrics beyond the specific transaction proceeds.
Material Changes
The primary material change is the settlement of legal disputes and the transfer of a mortgage promissory note. This transaction resulted in a one-time gain of approximately $106,000 for the quarter, representing the difference between the cash received and the asset's carrying value after write-downs.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, updated management commentary on future operations, or specific risk factors beyond the resolution of the previously reported litigation. The unusual item noted is the $106,000 gain from the sale of the Mortgage Note.
Investor Verification Checklist
- Verify the exact timing of the $1,400,000 cash receipt (February 9, 2018) against the company's cash flow statement.
- Confirm the accounting treatment of the $106,000 gain in the upcoming quarterly earnings report.
- Ensure all claims against Daniel Fisher and 580 Garcia Properties LLC are fully extinguished as stated.
- Review the specific write-downs applied to the Mortgage Note to understand the valuation adjustment.